PARIS — Sensome, a French medical technology company specializing in real-time microsensing tools, announced it has completed patient enrollment in its first-in-human INSPECT study. The clinical trial is evaluating a novel tumor detection system designed to identify cancerous tissue in situ during transbronchial lung biopsies.
The multi-center, single-arm study enrolled 27 patients and aims to assess the ability of Sensome’s technology to distinguish between healthy and cancerous tissue during bronchoscopic procedures. The device, integrated into a wire-like sensor inserted through a standard biopsy needle, is engineered to confirm whether the needle is correctly placed within a tumor — without the need for traditional imaging, which often fails to clearly detect malignant tissue in real time.
The technology could represent a significant advance in lung cancer diagnostics, offering bronchoscopists a tool to more accurately target biopsy sites and potentially reduce delays in diagnosis and treatment. Lung cancer remains the leading cause of cancer-related deaths worldwide, underscoring the need for innovations that can improve diagnostic precision.
“We are very encouraged by our experience using the Sensome tumor detection technology,” said Dr. Amir Hanna, coordinating investigator of the INSPECT study and an interventional pulmonologist at Lannelongue Hospital in France. “It has significant potential to make lung biopsies more efficient and, ultimately, improve how we treat lung cancer.”
Dr. David Fielding, a principal investigator at Royal Brisbane and Women’s Hospital in Australia, noted the system’s ease of use. “We found the technology easy to integrate into our bronchoscopy workflow, as it resembles the current stylet we typically use,” he said.
Franz Bozsak, CEO and co-founder of Sensome, expressed appreciation for the clinical teams involved and emphasized the broader impact of the technology. “We thank the investigators and their teams for their commitment to this important lung cancer research,” Bozsak said. “We look forward to sharing the results later this year, which will add to the growing clinical evidence supporting our microsensor technology across multiple therapeutic areas, including lung cancer, ischemic stroke, and peripheral vascular disease.”
The results of the INSPECT study are expected to be released in the coming months and could pave the way for broader clinical adoption of Sensome’s technology in oncology and beyond.
